Positron emission tomography in radiation treatment planning: The potential of metabolic imaging

Radiologic Clinics of North America

Volumn 51, Issue 5, 2013, Pages 913-925

  Chino, Junzo ^a   Das, Shiva ^a   Wong, Terence ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adaptive planning; Functional imaging; Metabolic imaging; Positron emission tomography; Radiation therapy

Indexed keywords

3' FLUOROTHYMIDINE F 18; COBALT 60; FLUORODEOXYGLUCOSE F 18;

BRAIN METASTASIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; GLUCOSE METABOLISM; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME;

ADAPTIVE PLANNING; FUNCTIONAL IMAGING; METABOLIC IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIATION THERAPY;

HUMANS; LYMPHATIC METASTASIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 84883449740     PISSN: 00338389     EISSN: 15578275     Source Type: Journal    
DOI: 10.1016/j.rcl.2013.05.007     Document Type: Review

References (50)

1. Erdi Y.E., Mawlawi O., Larson S.M., et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 1997, 80:2505-2509.
2. Patz E.F., Lowe V.J., Hoffman J.M., et al. Persistent or recurrent bronchogenic carcinoma-detection with PET and 2-F-18-2-deoxy-D-glucose. Radiology 1994, 191:379-382.
3. Nestle U., Kremp S., Schaefer-Schuler A., et al. Comparison of different methods for delineation of F-18-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. JNucl Med 2005, 46:1342-1348.
4. Black Q.C., Grills I.S., Kestin L.L., et al. Defining a radiotherapy target with positron emission tomography. Int J Radiat Oncol Biol Phys 2004, 60:1272-1282.
5. Jentzen W., Freudenberg L., Eising E.G., et al. Segmentation of PET volumes by iterative image thresholding. JNucl Med 2007, 48:108-114.
6. Werner-Wasik M., Nelson A.D., Choi W., et al. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom. Int J Radiat Oncol Biol Phys 2012, 82:1164-1171.
7. Geets X., Lee J.A., Bol A., et al. Agradient-based method for segmenting FDG-PET images: methodology and validation. Eur J Nucl Med Mol Imaging 2007, 34:1427-1438.
8. Li H., Thorstad W.L., Biehl K.J., et al. Anovel PET tumor delineation method based on adaptive region-growing and dual-front active contours. Med Phys 2008, 35:3711-3721.
9. Bentzen S.M., Gregoire V. Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol 2011, 21:101-110.
10. Aerts H., Lambin P., De Ruysscher D. FDG for dose painting: a rational choice. Radiother Oncol 2010, 97:163-164.
11. Meijer G., Steenhuijsen J., Bal M., et al. Dose painting by contours versus dose painting by numbers for stage II/III lung cancer: Practical implications of using a broad or sharp brush. Radiother Oncol 2011, 100:396-401.
12. Vanderstraeten B., Duthoy W., De Gersem W., et al. F-18 fluoro-deoxy-glucose positron emission tomography (F-18 FDG-PET) voxel intensity-based intensity-modulated radiation therapy (IMRT) for head and neck cancer. Radiother Oncol 2006, 79:249-258.
13. Das S.K., Miften M.M., Zhou S., et al. Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. Med Phys 2004, 31:1452-1461.
14. Alber M., Paulsen F., Eschmann S.M., et al. On biologically conformal boost dose optimization. Phys Med Biol 2003, 48:N31-N35.
15. Geets X., Tomsej M., Lee J.A., et al. Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy. Radiother Oncol 2007, 85:105-115.
16. Aerts H., Bosmans G., van Baardwijk A.A., et al. Stability of F-18-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study. Int J Radiat Oncol Biol Phys 2008, 71:1402-1407.
17. Madani I., Duprez F., Boterberg T., et al. Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. Radiother Oncol 2011, 101:351-355.
18. Higgins K.A., Hoang J.K., Roach M.C., et al. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUV(mean) has superior prognostic value. Int J Radiat Oncol Biol Phys 2012, 82:548-553.
19. Gupta T., Jain S., Agarwal J.P., et al. Diagnostic performance of response assessment FDG-PET/CT in patients with head and neck squamous cell carcinoma treated with high-precision definitive (chemo)radiation. Radiother Oncol 2010, 97:194-199.
20. Day F.L., Link E., Ngan S., et al. FDG-PET metabolic response predicts outcomes in anal cancer managed with chemoradiotherapy. Br J Cancer 2011, 105:498-504.
21. 18FDG-PET. Int J Radiat Oncol Biol Phys 2011, 80:91-96.
22. Martoni A.A., Di Fabio F., Pinto C., et al. Prospective study on the FDG-PET/CT predictive and prognostic values in patients treated with neoadjuvant chemoradiation therapy and radical surgery for locally advanced rectal cancer. Ann Oncol 2011, 22:650-656.
23. Passero V.A., Branstetter B.F., Shuai Y., et al. Response assessment by combined PET-CT scan versus CT scan alone using RECIST in patients with locally advanced head and neck cancer treated with chemoradiotherapy. Ann Oncol 2010, 21:2278-2283.
24. Huang W., Zhou T., Ma L., et al. Standard uptake value and metabolic tumor volume of (18)F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2011, 38:1628-1635.
25. van Loon J., Offermann C., Ollers M., et al. Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study. Radiother Oncol 2011, 99:172-175.
26. Janssen M.H., Ollers M.C., Riedl R.G., et al. Accurate prediction of pathological rectal tumor response after two weeks of preoperative radiochemotherapy using (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography imaging. Int J Radiat Oncol Biol Phys 2010, 77:392-399.
27. Wiegman E.M., Pruim J., Ubbels J.F., et al. (18)F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study. Eur J Nucl Med Mol Imaging 2011, 38:1059-1063.
28. Boellaard R. Standards for PET image acquisition and quantitative data analysis. JNucl Med 2009, 50:11S-20S.
29. Boellaard R., Oyen W.J., Hoekstra C.J., et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008, 35:2320-2333.
30. Wu Q.J., Li T., Wu Q., et al. Adaptive radiation therapy: technical components and clinical applications. Cancer J 2011, 17:182-189.
31. Castadot P., Geets X., Lee J.A., et al. Adaptive functional image-guided IMRT in pharyngo-laryngeal squamous cell carcinoma: is the gain in dose distribution worth the effort?. Radiother Oncol 2011, 101(3):343-350.
32. Simone C.B., Ly D., Dan T.D., et al. Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer. Radiother Oncol 2011, 101(3):376-382.
33. Guckenberger M., Wilbert J., Richter A., et al. Potential of adaptive radiotherapy to escalate the radiation dose in combined radiochemotherapy for locally advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2011, 79:901-908.
34. Shields A.F. PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. JNucl Med 2003, 44:1432-1434.
35. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. JNucl Med 2010, 51:866-874.
36. Han D., Yu J., Yu Y., et al. Comparison of (18)F-fluorothymidine and (18)F-fluorodeoxyglucose PET/CT in delineating gross tumor volume by optimal threshold in patients with squamous cell carcinoma of thoracic esophagus. Int J Radiat Oncol Biol Phys 2010, 76:1235-1241.
37. Patel D.A., Chang S.T., Goodman K.A., et al. Impact of integrated PET/CT on variability of target volume delineation in rectal cancer. Technol Cancer Res Treat 2007, 6:31-36.
38. Grosu A.L., Weber W.A. PET for radiation treatment planning of brain tumours. Radiother Oncol 2010, 96:325-327.
39. 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. JNucl Med 2010, 51:528-534.
40. van Waarde A., Elsinga P.H. Proliferation markers for the differential diagnosis of tumor and inflammation. Curr Pharm Des 2008, 14:3326-3339.
41. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. JNucl Med 2007, 48:726-735.
42. Rajendran J.G., Hendrickson K.R., Spence A.M., et al. Hypoxia imaging-directed radiation treatment planning. Eur J Nucl Med Mol Imaging 2006, 33(Suppl 1):44-53.
43. Hoigebazar L., Jeong J.M. Hypoxia imaging agents labeled with positron emitters. Recent Results Cancer Res 2012, 194:285-299.
44. Thorwarth D., Alber M. Implementation of hypoxia imaging into treatment planning and delivery. Radiother Oncol 2010, 97:172-175.
45. Brizel D.M., Sibley G.S., Prosnitz L.R., et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997, 38:285-289.
46. Hendrickson K., Phillips M., Smith W., et al. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 2011, 101:369-375.
47. Choi W., Lee S.W., Park S.H., et al. Planning study for available dose of hypoxic tumor volume using fluorine-18-labeled fluoromisonidazole positron emission tomography for treatment of the head and neck cancer. Radiother Oncol 2010, 97:176-182.
48. Lee N.Y., Mechalakos J.G., Nehmeh S., et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2008, 70:2-13.
49. Grosu A.L., Souvatzoglou M., Roper B., et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 69:541-551.
50. 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys 2008, 70:1219-1228.